ClinicalTrials.gg
RecruitingNCT02829684Updated Feb 20, 2024

Register of Patients With Prader-Willi Syndrome

An observational study in Prader-Willi Syndrome, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2009; still recruiting 17 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse — 6 open to participants now, 6 under way, 1 of them phase 3. Prader-Willi Syndrome · University Hospital, Toulouse.

Started
2009
with 2 others
Observational
3 of 17
3 open now
Registered
7th of 17
by date

Among the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, this one is one of 3 that started in 2009, is one of 3 observational ones, and was the 7th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

6 of the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Prader-Willi Syndrome (PWS) is a rare syndrome with a prevalence of 15 to 20 000 at birth. PWS represents a large fraction of mental retardation syndromes due to a genetic cause and the most frequent cause of genetic obesity. The majority of the patients are seen by paediatricians. This syndrome is responsible for severe physical, psychological and social impairments.

The diversity and the severity of the manifestations of this disease explain the requirement of multidisciplinary care which deserve specific evaluation. Today the follow-up and management of a great proportion of these patients are greatly insufficient if not absent.

Teams strongly lack information on the natural history of this severe disease and on the factors involved in its evolution and the outcome of these patients throughout life. The present project is to implement a register in the whole country for children and adult patients

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be included by the paediatric endocrinologists or the endocrinologists for adults of each region based on their own recruitment

Inclusion criteria

  • all subjects with a Prader-Willi Syndrome

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • OtherData collection

    This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.

06

What researchers measure

Primary outcomes

  1. collect data about patients

    Circumstances of diagnosis, genetic diagnosis, modalities of follow-up and clinical management and a questionnaire to evaluate quality of life of the family and social data

    Time frame: Baseline

Secondary outcomes

  1. collect data about patients

    modalities of follow-up and clinical management and a questionnaire to evaluate quality of life of the family and social data

    Time frame: During 10 years at least

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Children
    Toulouse, 31059, France
    Recruiting
08

References and documents

Publications

  • Pacoricona Alfaro DL, Lemoine P, Ehlinger V, Molinas C, Diene G, Valette M, Pinto G, Coupaye M, Poitou-Bernert C, Thuilleaux D, Arnaud C, Tauber M. Causes of death in Prader-Willi syndrome: lessons from 11 years' experience of a national reference center. Orphanet J Rare Dis. 2019 Nov 4;14(1):238. doi: 10.1186/s13023-019-1214-2. PubMed 31684997 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2009 (actual). Primary completion is estimated for Dec 2025, 201 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2016
First posted
Jul 12, 2016
StartActual
Mar 2009
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02829684
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Mar 2009
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 20, 2024

Study contacts

TAUBER Maité, MD PhD
Contact
tauber.m@chu-toulouse.fr
MOLINAS Catherine, CRA
Contact
molinas.c@chu-toulouse.fr
Tauber Maité, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion